Program
Insulin Glargine
Also written as “insulin glargine”, “Insulin glargine” and “INSULIN GLARGINE”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus, Type 1 · Diabetes Mellitus · Hyperglycemia · Glucose Intolerance, led by 9 companies.
Drug pageInsulin Glargine: every studyMany companies study it; this page follows only the 184 they lead. All 294 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 1241 open or running | phase 4since Sep 9, 2005 | Sep 30, 2002 | none ahead |
| Novo Nordiskits history only | 280 open or running | phase 4since Sep 12, 2005 | Oct 29, 2004 | none ahead |
| Eli Lillyits history only | 250 open or running | phase 4since Sep 12, 2005 | Sep 12, 2005 | none ahead |
| Diabetes Care Centerits history only | 20 open or running | no phasesince Apr 3, 2007 | Apr 3, 2007 | none ahead |
| Biodelits history only | 10 open or running | phase 2since Oct 21, 2009 | Oct 21, 2009 | none ahead |
| Geropharmits history only | 10 open or running | no phasesince Sep 23, 2019 | Sep 23, 2019 | none ahead |
| ikfe-CROits history only | 10 open or running | phase 4since Dec 5, 2011 | Dec 5, 2011 | none ahead |
| Profil Institut für Stoffwechselforschungits history only | 10 open or running | phase 1since Sep 3, 2009 | Sep 3, 2009 | none ahead |
| Wockhardtits history only | 10 open or running | phase 1since May 12, 2011 | May 12, 2011 | none ahead |
Also a collaborator on its studies: PPD DEVELOPMENT, LP, Alkermes and Boehringer Ingelheim.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Sanofi only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 45 studies since Jun 16, 2010.
- Aug 14, 2017Phase 4 study in Diabetes Mellitus, Type 1NCT03260868 · 15 enrolled · United States, Canada
- Nov 21, 2017Phase 4 study in Diabetes Mellitus, Type 2NCT03359837 · 384 enrolled · China
- Jan 15, 2018Phase 4 study in Diabetes Mellitus, Type 1NCT03406000 · 170 enrolled · Brazil
- Feb 9, 2018Phase 3 study in Diabetes Mellitus, Type 2NCT03434119 · 241 enrolled · United States
- May 7, 2018Phase 3 study in Diabetes Mellitus, Type 2NCT03529123 · 247 enrolled · India
- Nov 29, 2018Phase 4 study in Diabetes Mellitus, Type 2NCT03760991 · 372 enrolled · Argentina, Colombia, Egypt and more
- Dec 5, 2018Phase 3 study in Diabetes Mellitus, Type 2NCT03767543 · 265 enrolled · Canada
- Jan 7, 20192 phase 3 studies in Diabetes Mellitus, Type 2NCT03798080, NCT03798054
- Aug 29, 2019Phase 4 study in Diabetes Mellitus, Type 1NCT04075513 · 343 enrolled · United States, Brazil, Germany and more
- Jul 19, 2021Phase 4 study in Diabetes Mellitus, Type 2NCT04980027 · 228 enrolled · India
- Oct 29, 2021Phase 4 study in Diabetes Mellitus, Type 2NCT05114590 · 124 enrolled · United States
- Jun 7, 2022Phase 3 study in Diabetes Mellitus, Type 2NCT05413369 · 582 enrolled · China
- Sep 7, 2022Phase 4 study in Diabetes Mellitus, Type 2NCT05552859 · 62 enrolled · United States, Czechia, Hungary and more
- Oct 31, 2024Phase 4 study in Diabetes Mellitus, Type 2NCT06671587 · 678 planned · China
TargetBeta
“Insulin receptor agonist”ChEMBL 37, by rule
Other programs on INSR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Insulin Aspartrule | Novo Nordisk | phase 4 | 146 |
| insulin degludecrule | Novo Nordisk | phase 4 | 108 |
| Insulinrule | Pfizer | phase 4 | 50 |
| insulin glulisinerule | Sanofi | phase 4 | 43 |
| insulin icodecrule | Novo Nordisk | phase 4 | 30 |
| linsitinibrule | Astellas Pharma | phase 3 | 13 |
| LY3938577 | Eli Lilly | phase 2 | 3 |
Studies
The newest 60 of 124 Sanofi leads. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06671587Diabetes Mellitus, Type 2 · China | 4 | Recruiting | Sep 18, 2026 | 678 |
| NCT05552859Diabetes Mellitus, Type 2 · United States, Czechia, Hungary and more | 4 | Terminated | Jul 28, 2023 | 62 |
| NCT05413369Diabetes Mellitus, Type 2 · China | 3 | Completed | Oct 20, 2023 | 582 |
| NCT05114590Diabetes Mellitus, Type 2 · United States | 4 | Completed | Mar 28, 2023 | 124 |
| NCT04980027Diabetes Mellitus, Type 2 · India | 4 | Completed | Dec 23, 2022 | 228 |
| NCT04075513Diabetes Mellitus, Type 1 · United States, Brazil, Germany and more | 4 | Completed | Sep 16, 2021 | 343 |
| NCT03798080Diabetes Mellitus, Type 2 · China | 3 | Completed | Dec 1, 2020 | 426 |
| NCT03798054Diabetes Mellitus, Type 2 · China, Korea, Republic of, Malaysia and more | 3 | Completed | Mar 1, 2021 | 878 |
| NCT03767543Diabetes Mellitus, Type 2 · Canada | 3 | Completed | Oct 23, 2020 | 265 |
| NCT03760991Diabetes Mellitus, Type 2 · Argentina, Colombia, Egypt and more | 4 | Completed | Sep 23, 2020 | 372 |
| NCT03529123Diabetes Mellitus, Type 2 · India | 3 | Completed | Nov 25, 2019 | 247 |
| NCT03434119Diabetes Mellitus, Type 2 · United States | 3 | Terminated | Jan 7, 2019 | 241 |
| NCT03406000Diabetes Mellitus, Type 1 · Brazil | 4 | Completed | Feb 4, 2019 | 170 |
| NCT03359837Diabetes Mellitus, Type 2 · China | 4 | Completed | Jun 29, 2020 | 384 |
| NCT03260868Diabetes Mellitus, Type 1 · United States, Canada | 4 | Terminated | Nov 22, 2018 | 15 |
| NCT02967237Diabetes Mellitus, Type 2 · France | 4 | Completed | Jul 24, 2017 | 136 |
| NCT02967224Diabetes Mellitus, Type 2 · Brazil, France, Germany and more | 4 | Completed | Oct 16, 2017 | 705 |
| NCT02967211Diabetes Mellitus, Type 2 · Brazil, Finland, France and more | 4 | Completed | Oct 20, 2017 | 609 |
| NCT02855684Diabetes Mellitus, Type 2 · China, Korea, Republic of, Taiwan | 3 | Completed | Aug 6, 2018 | 604 |
| NCT02836704Diabetes Mellitus, Type 2 · China | 4 | Completed | Apr 26, 2018 | 892 |
| NCT02787551Diabetes Mellitus, Type 2 · United States, Canada, Estonia and more | 3 | Completed | May 25, 2018 | 514 |
| NCT02752828Diabetes Mellitus, Type 2 · Japan | 3 | Completed | Mar 12, 2018 | 521 |
| NCT02752412Diabetes Mellitus, Type 2 · Japan | 3 | Completed | Oct 4, 2018 | 513 |
| NCT02749890Diabetes Mellitus, Type 2 · Japan | 3 | Completed | May 2018 | 321 |
| NCT02738151Diabetes Mellitus, Type 2 · United States, Bulgaria, Croatia and more | 4 | Completed | Aug 15, 2017 | 929 |
| NCT02735044Diabetes Mellitus, Type 1 · United States, Argentina, Brazil and more | 3 | Completed | May 31, 2018 | 463 |
| NCT02713477Diabetes Mellitus, Type 2 · Japan | 1 | Completed | Jun 2016 | 20 |
| NCT02688933Diabetes Mellitus, Type 1 · United States, Puerto Rico | 4 | Completed | Jun 19, 2017 | 638 |
| NCT02606357Diabetes Mellitus, Type 2 · Jordan | 4 | Completed | Nov 27, 2017 | 242 |
| NCT02545842Diabetes Mellitus, Type 2 · China | 4 | Completed | Apr 20, 2018 | 947 |
| NCT02451137Diabetes Mellitus, Type 2 · United States, Canada | 4 | Completed | Mar 2, 2018 | 3,304 |
| NCT02401243Diabetes Mellitus, Type 2 · Canada | 3 | Completed | Feb 2016 | 253 |
| NCT02320721Diabetes Mellitus, Type 2 · United States, Argentina, Australia and more | 3 | Completed | May 2016 | 1,014 |
| NCT02227212Diabetes Mellitus, Type 2 · Germany | 3 | Completed | Nov 2014 | 40 |
| NCT02201199Diabetes Mellitus, Type 1 · Germany | 1 | Completed | Nov 2014 | 36 |
| NCT02058160Diabetes Mellitus, Type 2 · United States, Australia, Canada and more | 3 | Completed | Jul 2015 | 736 |
| NCT02058147Diabetes Mellitus, Type 2 · United States, Australia, Belgium and more | 3 | Completed | Jun 2015 | 1,170 |
| NCT02027753Diabetes Mellitus, Type 2 · Korea, Republic of | 4 | Completed | Apr 2015 | 109 |
| NCT01838083Type1 Diabetes · Germany | 1 | Completed | Aug 2013 | 50 |
| NCT01689142Diabetes Mellitus, Type 2 · Japan | 3 | Completed | Nov 2013 | 240 |
| NCT01689129Diabetes Mellitus, Type 1 · Japan | 3 | Completed | Oct 2013 | 243 |
| NCT01683266Diabetes Mellitus, Type 1 · United States, Canada, Czech Republic and more | 3 | Completed | Sep 2013 | 549 |
| NCT01676233Diabetes Mellitus, Type 1 · Japan | 1 | Completed | Aug 2013 | 20 |
| NCT01676220Diabetes Mellitus, Type 2 · United States, Bulgaria, Canada and more | 3 | Completed | Sep 2013 | 878 |
| NCT01658579Diabetes Mellitus, Type 1 · United States | 2 | Completed | May 2013 | 59 |
| NCT01499095Diabetes Mellitus, Type 2 · United States, Canada, Chile and more | 3 | Completed | Apr 2013 | 811 |
| NCT01499082Diabetes Mellitus, Type 2 · United States, Canada, Czechia and more | 3 | Completed | Jan 2013 | 807 |
| NCT01493115Diabetes Mellitus, Type 1 · Japan | 1 | Completed | Apr 2012 | 18 |
| NCT01476475Diabetes Mellitus, Type 2 · United States, Chile, Czech Republic and more | 2 | Completed | Dec 2012 | 323 |
| NCT01349855Diabetes Mellitus, Type 1 · Germany | 1 | Completed | May 2011 | 30 |
| NCT01336751Diabetes Mellitus, Type 2 · United States | 3 | Completed | Dec 2002 | 212 |
| NCT01234597Diabetes Mellitus, Type 2 · Israel | 4 | Completed | Apr 2015 | 219 |
| NCT01226043Diabetes Mellitus, Type 2 · United States | 4 | Completed | May 2012 | 405 |
| NCT01223131Diabetes Mellitus, Type 1 · China | 3 | Completed | Mar 2014 | 162 |
| NCT01212913Diabetes Mellitus, Type 2 · Korea, Republic of | 4 | Completed | May 2012 | 161 |
| NCT01204593Diabetes Mellitus, Type 1 · Algeria, Argentina, Brazil and more | 4 | Completed | Jan 2013 | 206 |
| NCT01202474Diabetes Mellitus, Type 1 · Russian Federation | 4 | Completed | Oct 2012 | 100 |
| NCT01195454Diabetes Mellitus, Type 1 · Germany | 1 | Completed | Nov 2010 | 24 |
| NCT01169818Diabetes Mellitus, Type 2 · China, India, Japan and more | 4 | Completed | Jun 2012 | 555 |
| NCT01146678Diabetes Mellitus, Type 1 · Germany | 1 | Completed | Sep 2010 | 22 |
How it is read
Names in the registry
- “insulin glargine”, 38 entries
- “Insulin Glargine”, 27 entries
- “Insulin glargine”, 20 entries
- “INSULIN GLARGINE”, 15 entries
- “LY2963016”, 11 entries
Codes read as this program: HOE901.
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 124 studies
- Diabetes Mellitus, Type 1, 44 studies
- Diabetes Mellitus, 14 studies
- Hyperglycemia, 1 study
- Glucose Intolerance, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.